PRINCETON, N.J. / Dec 22, 2023 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 42nd Annual Healthcare Conference in San Francisco, California, on Monday, January 8, 2024. Christopher Boerner, Ph.D., chief executive officer, will make a formal presentation and answer questions about the company at 7:30 a.m. PST/10:30 a.m. EST.
The event will be webcast simultaneously at http://investor.bms.com with materials related to the presentation available at the start of the live webcast. A replay and archived edition of the presentation will be available following the event.
About Bristol Myers Squibb Company
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.
| Last Trade: | US$45.10 |
| Daily Change: | 0.95 2.15 |
| Daily Volume: | 35,203,180 |
| Market Cap: | US$92.000B |
September 25, 2025 August 25, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
